implications of extended dosing of natalizumab on wearing-off symptoms in ms patients
Published 1 year ago • 78 plays • Length 4:33Download video MP4
Download video MP3
Similar videos
-
2:18
next-ms: personalized extended interval dosing of natalizumab in rrms
-
3:30
long-term efficacy outcomes of natalizumab vs. fingolimod in highly active rrms
-
3:59
the comparative effectiveness of natalizumab and ocrelizumab in naïve relapsing remitting ms
-
3:26
nfl to monitor treatment effects in ms
-
2:06
extending natalizumab's use without increasing risk to ms patients
-
1:30
differential efficacy of dmts in patients with active and inactive ms
-
3:55
dmts, long-term outcomes and transition to progressive ms
-
1:56
measuring the improvement of multiple sclerosis patients over time
-
3:23
mechanisms causing off episodes in parkinson disease
-
2:39
barcelona_brs to predict long-term prognosis in ms patients
-
1:47
the future of patient-reported outcomes in progressive ms
-
1:00
optimal dmt after natalizumab discontinuation
-
57:35
motor fluctuations and dyskinesia in parkinson's disease
-
2:08
phase iib study of mesdopetam for the treatment of dyskinesias in parkinson’s disease
-
3:31
the potential of btkis in multiple sclerosis
-
2:50
future of secondary progressive ms diagnosis and treatment
-
32:41
dr orla tuohy - dmts and ageing ms patients – what the ms nurse needs to know
-
1:37
the role of neuroinflammatory responses in parkinson’s disease